Enliven Therapeutics (ELVN) EBT (2019 - 2026)
Enliven Therapeutics (ELVN) reported EBT of -$27.9 million for Q1 2026, up 12.11% on a YoY basis from -$24.9 million in Q1 2025, and up 18.82% sequentially from -$34.4 million in Q4 2025.
Enliven Therapeutics (ELVN) EBT (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of EBT data on file, last reported at -$27.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 12.11% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$117.1 million (down 5.95% YoY), and the FY2025 full-year result was -$147.5 million, up 15.13% from the prior year.
- EBT advanced to -$27.9 million in Q1 2026, from -$34.4 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$8.9 million in Q1 2022 to a low of -$58.4 million in Q4 2023.
- A 5-year average of -$25.5 million and a median of -$26.1 million in 2024 frame the typical range for EBT.
- Across the five-year window, EBT plunged 120.32% in 2023 and surged 53.89% in 2024, its largest moves.
- Tracing ELVN's EBT over 5 years: stood at -$29.7 million in 2022, then sank by 96.61% to -$58.4 million in 2023, then surged by 53.89% to -$26.9 million in 2024, then declined by 27.7% to -$34.4 million in 2025, then climbed by 18.82% to -$27.9 million in 2026.
- Business Quant data shows ELVN's EBT at -$27.9 million in Q1 2026, -$34.4 million in Q4 2025, and -$25.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -27.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.93 Mn |
| Dec 31, 2025 | -34.40 Mn |
| Sep 30, 2025 | -25.61 Mn |
| Jun 30, 2025 | -29.20 Mn |
| Mar 31, 2025 | -31.78 Mn |
| Dec 31, 2024 | -26.94 Mn |
| Sep 30, 2024 | -27.15 Mn |
| Jun 30, 2024 | -24.69 Mn |
| Mar 31, 2024 | -26.07 Mn |
| Dec 31, 2023 | -58.42 Mn |
| Sep 30, 2023 | -24.67 Mn |
| Jun 30, 2023 | -20.25 Mn |
| Mar 31, 2023 | -16.44 Mn |
| Dec 31, 2022 | -29.71 Mn |
| Sep 30, 2022 | -11.20 Mn |
| Jun 30, 2022 | -9.46 Mn |
| Mar 31, 2022 | -8.90 Mn |
| Dec 31, 2021 | -14.38 Mn |
| Sep 30, 2021 | -13.91 Mn |
| Jun 30, 2021 | -17.00 Mn |